NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Granules Q2 FY27 Earnings Call: Revenue Crosses ₹1,560 Cr; US FDA Gagillapur Inspection Ends with 11 Form 483 Observations
Granules India reported its Q2 FY27 earnings transcript, crossing ₹1,500 Cr in quarterly revenue for the first time with ₹1,560 Cr (up 20% YoY) and PAT of ₹181.8 Cr (up 39% YoY). Operationally, the US FDA conducted a cGMP inspection of the Gagillapur facility from October 19 to October 30, 2026, issuing a Form 483 with 11 observations; management noted none relate to data integrity or cross-contamination. The company filed 3 potential sole first-to-file ANDAs over the last 3 quarters and has 26 ANDAs pending approval. Progress on the Senn CDMO/peptide platform includes an upcoming integrated peptide facility at Vizag and acceptable Swissmedic audit completion.
உச்சம் நம்பிக்கை
என்ன மாறியதுGranules released its Q2 FY27 conference call transcript detailing record quarterly revenue, peptide CDMO progress, and 11 US FDA observations at Gagillapur.
ஏன் இது முக்கியம்While top-line and PAT showed robust 20%+ growth, Gagillapur remains critical given past warning letter history, directly governing pending ANDA clearances.
📅 குறுகிய காலம்Focus will remain on the 15-day CAPA submission to the US FDA for Gagillapur and subsequent regulatory classification (VAI/OAI).
📈 நீண்ட காலம்The shift toward complex generics (>50% target), first-to-file ANDAs, and peptide CDMO expansion provides long-term margin improvement potential.
⚠ அபாய எச்சரிக்கைகள்
11 Form 483 observations at Gagillapur which was previously under a Warning Letter
Delay risk in product approvals tied to Gagillapur resolution
Input and logistics cost inflation from geopolitical developments
👀 கவனிக்க வேண்டியவை
Track the resolution status of the 11 Form 483 observations at the Gagillapur site (timing of EIR issuance) and its impact on the 9 pending product approvals.
Granules India Q2 FY27 Investor Presentation: Revenue up 20% to ₹1,560 Cr, PAT up 39% to ₹181.8 Cr
Granules India reported a 20% YoY increase in revenue to ₹1,560 Cr for Q2 FY27, with EBITDA climbing 21% YoY to ₹337.6 Cr and PAT rising 39% YoY to ₹181.8 Cr. Operating performance was driven by a 45% YoY jump in Complex Generics revenue, while Gross Margins contracted by 134 bps YoY to 64.4% due to higher input and West Asia freight costs. The company turned net cash with ₹828 Cr following the receipt of balance warrant proceeds. Additionally, US FDA inspection at Gagillapur concluded with observations that management expects to resolve through corrective actions.
உச்சம் நம்பிக்கை
என்ன மாறியதுGranules filed its Q2 FY27 investor presentation following the release of quarterly financial results, providing segment breakdowns, pipeline details, and balance sheet updates.
ஏன் இது முக்கியம்Demonstrates robust revenue and profit growth led by high-margin Complex Generics, while strengthening the balance sheet to a net cash position to fund planned organic capex of ~₹2,000 Cr over 3-4 years.
📅 குறுகிய காலம்Markets are likely to react positively to strong top-line and bottom-line expansion, though input and shipping headwinds will keep margin expansion in check in the near term.
📈 நீண்ட காலம்The structural shift toward Complex Generics, 3 potential first-to-file Para IV opportunities, and scaling the Senn Chemicals peptide platform provide sustained multi-year growth runway.
⚠ அபாய எச்சரிக்கைகள்
Pending outcome/formal classification of Gagillapur US FDA audit observations
Ongoing EBITDA losses in Peptide CDMO segment (₹152 Mn in Q2 FY27)
Input cost and logistics pressures due to West Asia geopolitical tensions
👀 கவனிக்க வேண்டியவை
Track the outcome and final classification of the Gagillapur US FDA inspection, as well as the path to EBITDA breakeven for the newly acquired Senn Chemicals peptide CDMO business.
Granules India Q2 Standalone PAT at ₹108.5 Cr; ₹1,096 Cr Inflow from Warrant Conversion
Granules India reported standalone revenue from operations of ₹947.82 Cr for Q2 FY27 (quarter ended Sep 30, 2026), up 6.3% YoY compared to ₹891.61 Cr in Q2 FY26. Standalone net profit stood at ₹108.52 Cr, down 10.0% YoY from ₹120.61 Cr. During the quarter, warrant holders converted 24,982,906 warrants into equity shares, bringing in balance subscription funds of ₹1,096.13 Cr (amounting to ~5.4% of market cap). Additionally, USFDA reinspected the Gagillapur facility in October 2026 and issued Form 483 with observations that did not involve data integrity or cross-contamination.
உச்சம் நம்பிக்கை
என்ன மாறியதுGranules India approved its Q2 FY27 results, allotted 24.98 million equity shares upon warrant exercise, and expanded its global footprint with new entities in Brazil and Mexico.
ஏன் இது முக்கியம்The warrant conversion delivers ₹1,096 Cr in cash to significantly bolster the balance sheet and support ongoing CDMO/peptide expansions, though Q2 standalone margins saw compression.
Standalone Revenue (Q2): ₹9,478.21 MnStandalone PAT (Q2): ₹1,085.16 MnWarrant conversion inflow: ₹10,961.25 MnWarrant inflow vs Net Worth: ~24.9%Shares allotted on warrant conversion: 24,982,906
📅 குறுகிய காலம்Earnings show muted operational growth while the final resolution of the USFDA Gagillapur audit remains the key regulatory overhang to watch in coming weeks.
📈 நீண்ட காலம்Substantial equity capital addition strengthens liquidity for capex and international formulation expansion across LATAM and North America.
⚠ அபாய எச்சரிக்கைகள்
Pending regulatory clearance from USFDA following Form 483 issuance at Gagillapur facility
Equity dilution from conversion of 24.98 million warrants into equity shares
Raw material cost pressures impacting standalone net profitability YoY
👀 கவனிக்க வேண்டியவை
Monitor the company's formal response to the USFDA Form 483 for the Gagillapur facility and track the deployment of the ₹1,096 Cr warrant proceeds toward debt reduction or CDMO capex.
Granules India Gets 11 USFDA Observations at Gagillapur Facility Following cGMP Inspection
Granules India's finished dosage facility at Gagillapur, Hyderabad, completed a USFDA cGMP inspection with a Form FDA 483 containing 11 observations. The inspection took place between October 19 and October 30, 2026, marking the facility's first inspection since receiving a Warning Letter on February 26, 2025. The company stated there is no impact on ongoing manufacturing or distribution, and none of the observations relate to data integrity or cross-contamination. Granules has committed to submitting its corrective action plan within the standard 15 business days.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Gagillapur facility concluded its reinspection post-February 2025 Warning Letter, receiving 11 procedural observations via Form FDA 483.
ஏன் இது முக்கியம்Gagillapur is a core finished dosage facility; clearing regulatory scrutiny is vital to lifting the Warning Letter and unlocking pending US generic product approvals.
Number of observations: 11Inspection dates: அக்டோபர் 19 to அக்டோபர் 30, 2026Response deadline: 15 business daysPrevious Warning Letter date: பிப்ரவரி 26, 2025
📅 குறுகிய காலம்Expect market caution as 11 observations is a relatively high count, though lack of data integrity issues provides partial relief pending USFDA's final classification.
📈 நீண்ட காலம்Resolution of these observations is critical for accelerating US generic growth, which is currently a key growth factor for Granules' TTM revenue base of Rs 5,633 Cr.
⚠ அபாய எச்சரிக்கைகள்
Escalation risk if USFDA deems the 11 observations inadequate to lift the prior Warning Letter
Potential delays in new ANDA approvals from the Gagillapur site
👀 கவனிக்க வேண்டியவை
Track the formal submission of the response within 15 business days and subsequent USFDA classification (VAI vs OAI) to verify whether the 2025 Warning Letter is lifted.
Granules Gains Potential Sole First-to-File Status for Ruxolitinib ER Tablets ANDA
Granules India Limited has submitted an ANDA with a Paragraph IV certification for Ruxolitinib Extended-Release Tablets. Based on the filing timeline, the company believes it is eligible for sole first-to-file status, which could grant 180 days of generic marketing exclusivity under U.S. law upon approval. The filing represents Granules' ongoing push into higher-value, technically complex generic formulations in the U.S. market. However, the application remains subject to FDA review, Paragraph IV litigation risks, and final determination of exclusivity status.
உச்சம் நம்பிக்கை
என்ன மாறியதுGranules submitted a Paragraph IV ANDA for generic Ruxolitinib Extended-Release Tablets, positioning itself as a potential sole first-to-file applicant.
ஏன் இது முக்கியம்A confirmed first-to-file status with 180-day marketing exclusivity provides high-margin commercialization opportunities in the U.S., diversifying Granules away from standard commodity generics.
Exclusivity Period: 180 நாட்கள்Total Manufacturing Facilities: 10Market Presence: over 80 countries
📅 குறுகிய காலம்Watch for the response from patent holders within the statutory 45-day window which may trigger standard Hatch-Waxman patent litigation.
📈 நீண்ட காலம்If successfully defended and approved with exclusivity, it supports Granules' strategy to expand into higher-margin, differentiated U.S. generic formulations.
⚠ அபாய எச்சரிக்கைகள்
Potential patent litigation from the innovator leading to a 30-month stay of approval
Exclusivity and ANDA remain pending final US FDA review and confirmation
👀 கவனிக்க வேண்டியவை
Track whether the innovator initiates patent litigation within 45 days of notice, along with future FDA approval timelines and exclusivity confirmation.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Granules India Allots 2.50 Cr Equity Shares on Warrant Conversion; Raises ₹1,461.50 Cr
Granules India Limited has allotted 2,49,82,906 equity shares of face value Re. 1/- each to promoter group members upon conversion of warrants. The conversion was executed at an issue price of ₹585 per share, representing total proceeds of ₹1,461.50 crore (including the initial 25% upfront subscription). This equity infusion is substantial, equivalent to ~28.4% of TTM revenue (₹5,140 Cr) and ~7.1% of the company's current market cap. The total paid-up equity share capital expands from 24,77,96,921 to 27,27,79,827 shares, leaving 17,094 non-promoter warrants outstanding.
உச்சம் நம்பிக்கை
என்ன மாறியதுGranules India converted 2.50 crore warrants into fully paid-up equity shares for promoter group entities after receiving the balance 75% subscription money.
ஏன் இது முக்கியம்The company has received ₹1,461.50 crore in total capital, which significantly strengthens its net worth, de-leverages the balance sheet, and provides dry powder for ongoing growth initiatives (such as Senn Chemicals and Ascelis).
Shares allotted: 2,49,82,906Issue / Exercise price: Rs. 585/- per shareTotal consideration: Rs. 1,461.50 CroresFundraise vs TTM Revenue: ~28.4%Fundraise vs Market Cap: ~7.1%Post-issue share count: 27,27,79,827
📅 குறுகிய காலம்Signals strong promoter commitment via cash infusion at ₹585/share, though the addition of ~2.50 crore shares (~10% equity expansion) causes slight EPS dilution.
📈 நீண்ட காலம்Substantially fortifies the balance sheet and liquidity profile to fund CDMO capex and peptide portfolio scaling, lowering leverage risks.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~10% impacting future earnings per share (EPS)
Execution risk on deploying large cash reserves profitably into planned CDMO and peptide assets
👀 கவனிக்க வேண்டியவை
Track the upcoming quarterly shareholding patterns to verify updated promoter equity totals, and monitor management commentary regarding the deployment of proceeds toward CDMO/peptide expansions or debt reduction.
Granules India Receives ₹1,093 Cr from Promoters for Warrant Conversion; Turns Net Cash Surplus
Granules India announced that its promoter group has remitted the balance 75% subscription amount of ₹1,093 crore towards preferential convertible warrants. Consequently, 2,49,14,530 warrants are fully paid and eligible for conversion into equity shares. The capital infusion turns the company into a net cash surplus position on a consolidated basis, significantly exceeding its existing total debt of ₹828 crore. The proceeds will provide growth capital to accelerate business initiatives and capital expenditure ahead of schedule.
உச்சம் நம்பிக்கை
என்ன மாறியதுPromoters completed the payment of ₹1,093 crore to convert 2.49 crore warrants into equity, wiping out net debt.
ஏன் இது முக்கியம்The infusion strengthens the balance sheet to a net cash position and provides substantial dry powder to fund strategic growth and acquisitions without external debt.
Balance subscription received: ரூ. 1,093 கோடிWarrants eligible for conversion: 2,49,14,530Balance payment percentage: 75%Inflow vs Net Worth: ~24.8%Inflow vs Total Debt: ~132%
📅 குறுகிய காலம்Strengthens sentiment as promoters inject substantial equity cash, de-leveraging the balance sheet to a net cash status.
📈 நீண்ட காலம்Accelerates long-term CAPEX and strategic M&A investments (e.g., Senn Chemicals, peptides) while improving return ratios and financial resilience.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from the issuance of ~2.49 crore fresh equity shares upon conversion
👀 கவனிக்க வேண்டியவை
Track the formal board allotment and listing of the 2,49,14,530 equity shares, along with updates on capital deployment towards CDMO and peptide expansion.
Promoter Sells 1.72 Cr Shares in Granules India; Group Stake Drops to 31.08%
Promoter Dr. Krishna Prasad Chigurupati sold 1,72,00,000 equity shares of Granules India on September 11, 2026, through block deals and the open market. Following the stake sale, aggregate Promoter and Promoter Group holding reduced from 38.02% to 31.08% (37.39% on a diluted basis). Dr. Chigurupati's individual holding fell from 31.00% to 24.06%. The proceeds will be used to fund the second tranche of the company's ongoing preferential issue and finance strategic growth initiatives.
உச்சம் நம்பிக்கை
என்ன மாறியதுPromoter Dr. Krishna Prasad Chigurupati offloaded 1.72 crore shares, cutting overall promoter stake to 31.08% from 38.02%.
ஏன் இது முக்கியம்While promoter selling typically causes overhang, the proceeds are earmarked to fund a preferential issue back into the company to support faster-than-expected expansion.
Shares Sold: 1,72,00,000 equity sharesPromoter Group Pre-deal Stake: 38.02%Promoter Group Post-deal Stake: 31.08%Promoter Group Diluted Post-deal Stake: 37.39%Dr. Chigurupati Post-deal Stake: 24.06%
📅 குறுகிய காலம்Large secondary market supply is absorbed by institutional buyers, limiting extreme downward price pressure, though supply absorption will be monitored over coming sessions.
📈 நீண்ட காலம்On a diluted basis, promoter ownership will rebound towards 37.39% as preferential issue warrants/shares are subscribed, providing growth capital for CDMO and generic expansion.
⚠ அபாய எச்சரிக்கைகள்
Reduction in undiluted promoter ownership down to 31.08%
Execution risk on growth projects requiring early capital deployment
👀 கவனிக்க வேண்டியவை
Track the infusion of funds from the preferential issue's second tranche into company balance sheets and watch for execution timelines of announced growth initiatives.
Granules India Appoints Sanjay Kumar as CEO of Ascelis Peptides Effective Aug 13, 2026
Granules India has internally transferred its Chief Strategy Officer, Mr. Sanjay Kumar, to the role of CEO at its wholly-owned subsidiary, Ascelis Peptides Private Limited, effective August 13, 2026. This move provides dedicated leadership to the company's peptide and specialized segments, which are central to its 15-20% growth target. Ascelis Peptides is a critical but currently loss-making unit, having reported an EBITDA loss of INR 20 Cr. The transition follows Granules' significant investments in the space, including the INR 450 Cr acquisition of Senn Chemicals AG.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Chief Strategy Officer of the parent company has been moved to lead a key growth subsidiary as its CEO.
ஏன் இது முக்கியம்It signals a shift from group-level strategy to execution-focused leadership for the specialized peptide business, which is vital for margin expansion beyond base generics.
📅 குறுகிய காலம்The market is likely to view this as a routine internal realignment with no immediate impact on the stock price.
📈 நீண்ட காலம்If successful, dedicated leadership at Ascelis could accelerate the company's transition into high-value CDMO and peptide markets, improving overall group ROCE.
⚠ அபாய எச்சரிக்கைகள்
Execution risk in turning around a loss-making subsidiary
Dependency on the success of the peptide portfolio for future margin growth
👀 கவனிக்க வேண்டியவை
Monitor the next two quarterly results for Ascelis Peptides to see if dedicated leadership leads to a reduction in EBITDA losses and faster product filings.
60% PAT Growth in Q1 FY27; Complex Generics Reach 50% of Finished Dosages
Granules India reported its strongest Q1 ever, with revenue growing 22% YoY to ₹1,477 cr and PAT surging 60% to ₹180 cr. The company is successfully shifting its product mix, with complex generics now accounting for 50% of finished dosages, up from 39% a year ago. Financial health is robust with ROCE improving to 18% and the company becoming virtually debt-free with a Net Debt/EBITDA of 0.07x. Management confirmed that remediation at the Gagillapur facility is complete, with 9 product applications currently awaiting regulatory clearance to launch.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully transitioned half of its finished dosage portfolio to complex generics and significantly deleveraged its balance sheet to near-zero net debt.
ஏன் இது முக்கியம்The shift toward complex generics and Peptides (CDMO) improves margins and ROCE (now 18%), reducing the company's historical dependence on high-volume, low-margin commodity generics.
Q1 வருவாய் vs TTM வருவாய்: 33%PAT Growth (YoY): 60%Complex Generics Share: 50%Net Debt/EBITDA: 0.07xFormulation Capacity Addition: 40%ROCE: 18%
📅 குறுகிய காலம்The stock is likely to react positively to the significant earnings beat and the improvement in cash flow and debt metrics.
📈 நீண்ட காலம்Structural shift toward innovation-led CDMO and complex generics provides a path for sustainable 15-20% growth and potential valuation re-rating.
👀 கவனிக்க வேண்டியவை
Monitor the US FDA's final clearance for the Gagillapur facility, which will unlock 9 pending product launches. Additionally, track the utilization ramp-up at the new Genome Valley facility, which adds 40% to total formulation capacity.
60% YoY PAT Growth to INR 1,800 Mn; Net Debt Reduced by INR 8,467 Mn in Q1 FY27
Granules India reported a robust Q1 FY27 with revenue increasing 22% YoY to INR 14,768 Mn, representing approximately 33% of TTM revenue. Net profit (PAT) surged 60% YoY to INR 1,800 Mn, supported by an improved EBITDA margin of 23% compared to 20% in the year-ago period. A significant highlight is the aggressive deleveraging, with net debt decreasing by INR 8,467 Mn YoY to just INR 1,012 Mn, resulting in a low Net Debt to EBITDA ratio of 0.07x. While North America remains the dominant market at 72% of revenue, the company is seeing growth in Europe and its new Peptides CDMO segment which now contributes 4% of revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுGranules reported its Q1 FY27 results showing strong double-digit growth in revenue and profits alongside a massive reduction in debt.
ஏன் இது முக்கியம்The significant jump in PAT and ROCE indicates improved operational efficiency and a successful shift toward higher-margin finished dosages and complex products, while the debt reduction strengthens the balance sheet for future expansions.
Revenue from Operations: INR 14,768 MnPAT: INR 1,800 MnNet Debt Reduction (YoY): INR 8,467 MnROCE: 18.0%Revenue vs TTM Revenue: ~33%Net Debt to EBITDA: 0.07x
📅 குறுகிய காலம்The stock is likely to react positively to the strong YoY profit growth and the significant improvement in the debt profile.
📈 நீண்ட காலம்Structural improvements in ROCE and the growing contribution from the Peptides CDMO segment suggest a successful transition toward a more complex and margin-accretive product portfolio.
⚠ அபாய எச்சரிக்கைகள்
High geographic concentration with 72% revenue from North America
Management warning on supply chain volatility for the next two quarters
Product concentration in top 5 molecules
👀 கவனிக்க வேண்டியவை
Watch the scaling of the Peptides CDMO business and the management's ability to navigate 'external cost pressures and supply chain volatility' mentioned for the next two quarters.
Granules Secures Sole First-to-File (FTF) Status for Sodium Oxybate ER Oral Suspension
Granules India has achieved Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) for Sodium Oxybate Extended-Release for Oral Suspension, the generic version of LUMRYZ®. This marks the company's second Sole FTF achievement, following its success with Amphetamine ER Tablets. Sole FTF status typically grants 180 days of market exclusivity in the U.S., which can lead to significantly higher margins and market share during the exclusivity period. This development aligns with Granules' strategy to transition from high-volume base generics to high-value complex generics.
உச்சம் நம்பிக்கை
என்ன மாறியதுGranules has transitioned from a standard generic filer to a Sole First-to-File status holder for a complex, differentiated product in the U.S. market.
ஏன் இது முக்கியம்Sole FTF status provides a temporary monopoly in the generic market, which is highly margin-accretive and helps diversify the company's revenue away from its top 5 commodity-like products.
Sole FTF ANDAs to date: 2Total Manufacturing Facilities: 11TTM வருவாய்: ₹ 4474 CrTTM Operating Profit Margin: 21.6%
📅 குறுகிய காலம்The announcement is likely to be viewed positively by the market as it validates the company's R&D pipeline and potential for high-margin U.S. sales.
📈 நீண்ட காலம்This reinforces Granules' structural shift toward complex generics and controlled substances, which is critical for long-term margin expansion and reducing pricing pressure from base generics.
⚠ அபாய எச்சரிக்கைகள்
Potential patent litigation from the innovator (Alkermes)
Regulatory compliance risks at manufacturing sites
Execution risk in commercializing complex oral suspensions
👀 கவனிக்க வேண்டியவை
Investors should monitor the U.S. FDA's final approval timeline and the subsequent commercial launch date to gauge the timing of the 180-day exclusivity period's impact on earnings.
Granules India Receives USFDA EIR with VAI Status for Chantilly Facility
Granules India's US-based subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received an Establishment Inspection Report (EIR) from the USFDA for its facility in Chantilly, Virginia. The inspection, which took place from March 30 to April 3, 2026, resulted in a Voluntary Action Indicated (VAI) classification. Although four Form 483 observations were issued during the audit, the VAI status indicates that the facility is considered to be in a state of compliance. This clearance is vital for the company's continued manufacturing and supply operations within the United States.
முக்கிய அம்சங்கள்
Received USFDA EIR for the Chantilly, Virginia facility with a VAI classification.The inspection was conducted between March 30 and April 3, 2026.Four Form 483 observations were issued during the inspection process.The Chantilly facility is a wholly-owned subsidiary and a key component of Granules' global supply network.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development as it resolves regulatory uncertainty regarding a key US manufacturing site. No immediate action is required, but this strengthens the company's compliance track record in regulated markets.
Granules India FY26 Revenue Hits ₹53,656 Mn; Gross Margin Rises to 65% on Complex Generic Shift
Granules India reported a strong FY26 with revenue growing 20% YoY to ₹53,656 million, crossing a major milestone. The company achieved record gross margins of 65%, up 355 basis points, driven by a strategic shift toward high-value complex generics. The newly acquired Senn Chemicals (Peptide CDMO) contributed ₹1,593 million in revenue and turned EBITDA positive in Q4. Despite ongoing regulatory remediation at the Gagillapur site, the company has maintained six consecutive quarters of sequential growth.
முக்கிய அம்சங்கள்
FY26 revenue reached ₹53,656 million, a 20% YoY increase, driven by strong performance in North America and Europe.Gross margins expanded to 65% due to improved product mix and the scaling of the Virginia (GPI) facility.The US subsidiary (GPI) jumped to the 27th position among US generic companies by sales value, up from 74th in FY21.Peptide CDMO vertical generated ₹1,593 million in FY26 revenue and achieved positive EBITDA in the final quarter.Europe revenue grew 81% YoY, now contributing 15% of the total revenue base.
👀 கவனிக்க வேண்டியவை
Investors should focus on the upcoming US FDA re-inspection of the Gagillapur facility, as 9 pending product approvals are tied to its clearance. The successful turnaround of the peptide business and margin expansion provide a strong foundation for FY27 growth.
Granules India FY26 Net Profit Jumps 25.5% to ₹4,007 Million; Revenue Up 14.6%
Granules India reported a strong performance for the financial year ended March 31, 2026, with annual revenue growing 14.6% YoY to ₹34,739.60 million. The company's net profit for the full year saw a significant increase of 25.5%, reaching ₹4,006.67 million compared to ₹3,193.36 million in the previous fiscal. For the fourth quarter, revenue grew 14.1% YoY to ₹8,768.21 million. The company also demonstrated improved financial health by reducing its current borrowings from ₹8,081.93 million to ₹7,336.80 million.
முக்கிய அம்சங்கள்
Annual Net Profit grew by 25.5% YoY to ₹4,006.67 million in FY26.Total Revenue from operations for FY26 increased to ₹34,739.60 million from ₹30,301.63 million.Q4 FY26 Revenue rose 14.1% YoY to ₹8,768.21 million compared to ₹7,680.26 million in Q4 FY25.Full-year Earnings Per Share (EPS) improved to ₹16.48 from ₹13.17 in the previous year.Current borrowings were reduced by ₹745.13 million during the fiscal year.
👀 கவனிக்க வேண்டியவை
The strong double-digit growth in both revenue and profitability, coupled with debt reduction, reflects high operational efficiency. Investors may consider this a positive signal for long-term value, though they should monitor the sustainability of margins in the competitive pharma sector.
Granules Q4FY26 PAT Jumps 33% YoY to INR 2,016 Mn; EBITDA Margins Expand to 24%
Granules India reported a strong Q4FY26 with revenue growing 23% YoY to INR 14,706 Mn and PAT increasing 33% YoY to INR 2,016 Mn. EBITDA margins saw a significant expansion to 24% from 21% in the previous year, driven by a better product mix and operational efficiencies. The company successfully reduced its net debt by INR 3,040 Mn over the year, bringing the Net Debt to EBITDA ratio down to a healthy 0.34x. Notably, the revenue share from Europe doubled to 17%, while the new Peptide/CDMO segment contributed 5% to the quarterly revenue.
முக்கிய அம்சங்கள்
Q4FY26 Revenue grew 23% YoY to INR 14,706 Mn, while PAT rose 33% YoY to INR 2,016 Mn.EBITDA margins expanded by 300 bps YoY to 24%, with EBITDA reaching INR 3,521 Mn (+40% YoY).Net debt significantly reduced by INR 3,040 Mn YoY to INR 4,021 Mn; Net Debt/EBITDA stands at 0.34x.Geographic diversification improved as Europe's revenue share rose to 17% from 8% YoY.Full-year FY26 ROCE improved to 17.6% compared to 16.6% in the previous fiscal year.
👀 கவனிக்க வேண்டியவை
Investors should view these results positively due to the strong margin expansion and significant deleveraging of the balance sheet. The growth in the high-margin Peptide/CDMO segment and increased European market penetration provide a promising outlook for future earnings quality.
Granules India FY26 Revenue Hits ₹53,656 Mn, Up 20%; PAT Grows 19% to ₹5,950 Mn
Granules India achieved a significant milestone in FY26, surpassing ₹50,000 Mn in revenue with 20% YoY growth. The company witnessed structural margin expansion, with gross margins reaching 65% driven by a strategic shift toward Complex Generics, which now account for 43% of formulation sales. Financial health improved significantly as Net Debt to EBITDA dropped to 0.34x from 0.75x. The newly launched CDMO vertical and an 81% surge in European revenue emerged as key growth catalysts.
முக்கிய அம்சங்கள்
FY26 Revenue grew 20% YoY to ₹53,656 Mn, surpassing the ₹50,000 Mn milestone for the first time.Gross Margin expanded by 355 bps to 65.0%, while EBITDA grew 25% YoY to ₹11,851 Mn.Complex Generics share in the Formulations segment increased to 43% from 31% in FY25.Net Debt to EBITDA improved to 0.34x, supported by an equity infusion of ₹6,656 Mn.Europe revenue grew by 81% YoY, and the new CDMO platform contributed ₹1,593 Mn in its first year.
👀 கவனிக்க வேண்டியவை
Investors should note the successful transition from volume-led to value-led growth through complex generics and CDMO services. The significant deleveraging and margin expansion provide a strong foundation for long-term capital appreciation.
Granules India FY26 PAT Jumps 25% to ₹4,007 Mn; Recommends ₹1.75 Final Dividend
Granules India reported a strong performance for the financial year ended March 31, 2026, with standalone revenue growing 14.6% YoY to ₹34,739.6 million. Net profit for the full year rose significantly by 25.5% to ₹4,006.67 million compared to ₹3,193.36 million in the previous year. The Board has recommended a final dividend of ₹1.75 per share, representing 175% of the face value. The company's balance sheet remains robust with total assets increasing to ₹59,812.79 million as of March 31, 2026.
முக்கிய அம்சங்கள்
Full-year FY26 Revenue from operations increased to ₹34,739.60 million from ₹30,301.63 million in FY25.Net Profit for FY26 grew by 25.5% YoY to ₹4,006.67 million.Board recommended a final dividend of ₹1.75 per share (175%) for the financial year 2025-26.Earnings Per Share (EPS) improved to ₹16.48 for the full year from ₹13.17 in the previous year.Standalone Q4 FY26 revenue stood at ₹8,768.21 million, up from ₹7,680.26 million in the same quarter last year.
👀 கவனிக்க வேண்டியவை
Investors should view the strong double-digit growth in both revenue and profitability as a positive sign of operational scaling. The consistent dividend payout and improved EPS make it a healthy pick for long-term pharmaceutical sector exposure.
Granules India Subsidiary Receives VAI Classification from US FDA for Shamirpet Facility
Granules India's wholly owned subsidiary, Granules Life Sciences, has received a Voluntary Action Indicated (VAI) classification from the US FDA for its Shamirpet facility in Telangana. The Establishment Inspection Report (EIR) follows a cGMP and pre-approval inspection conducted between December 15 and 19, 2025. The US FDA has officially closed the inspection with no regulatory actions recommended, providing a clear path for oral solid dosage manufacturing. This outcome enables multi-site manufacturing for approved products, enhancing the company's operational flexibility and supply chain reliability for the US market.
முக்கிய அம்சங்கள்
US FDA issued an Establishment Inspection Report (EIR) with VAI classification for the Shamirpet manufacturing unit.The inspection was conducted from December 15 to 19, 2025, covering oral solid dosage manufacturing operations.The regulatory body has officially closed the inspection and recommended no further regulatory actions.The clearance enables multi-site manufacturing capabilities for approved products across Granules' facility network.Granules India maintains a global footprint with 11 manufacturing facilities, including 8 in India and 2 in the USA.
👀 கவனிக்க வேண்டியவை
This is a positive regulatory development that de-risks the company's manufacturing operations and supports future product launches. Investors should maintain confidence in Granules' compliance track record and its ability to service the regulated US market.
Granules India's US Packaging Facility Receives US FDA EIR with NAI Status
Granules India's US subsidiary, Granules Consumer Health, LLC, has received an Establishment Inspection Report (EIR) with 'No Action Indicated' (NAI) status from the US FDA. The inspection was conducted at its Manassas, Virginia packaging facility between December 1 and 3, 2025. This marks the second consecutive time the facility has cleared an FDA audit with zero observations, following a similar result in March 2023. The facility serves as a critical distribution hub for the company's US front-end OTC and prescription product operations.
முக்கிய அம்சங்கள்
Received US FDA EIR with No Action Indicated (NAI) status for the Virginia packaging facility.The inspection was conducted from December 1 to 3, 2025, resulting in zero observations.Second consecutive successful FDA audit for this facility following the March 2023 inspection.The site operates three advanced packaging lines for OTC and prescription (Rx) products.Facility handles controlled substances and serves as a primary US distribution hub.
👀 கவனிக்க வேண்டியவை
This regulatory clearance confirms Granules' strong compliance culture and ensures no supply chain disruptions for its US OTC business. Investors should maintain a positive outlook on the stock given its consistent track record of zero-observation audits.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
